carbamates has been researched along with Peripheral Nerve Diseases in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "Joint inflammation was also measured in a separate cohort of animals treated on day 1 with either saline or the FAAH inhibitor URB597 (0." | 1.46 | Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice. ( Krustev, E; McDougall, JJ; Muley, MM; Philpott, HT; Reid, A, 2017) |
| " Cisplatin produces a cumulative toxic effect on peripheral nerves, and 30-40% of cancer patients receiving this agent experience pain." | 1.38 | Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. ( Harding-Rose, C; Khasabov, S; Khasabova, IA; Paz, J; Seybold, VS; Simone, DA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| da Motta, KP | 1 |
| Santos, BF | 1 |
| Domingues, NLC | 1 |
| Luchese, C | 1 |
| Wilhelm, EA | 1 |
| McDougall, JJ | 1 |
| Muley, MM | 1 |
| Philpott, HT | 1 |
| Reid, A | 1 |
| Krustev, E | 1 |
| Li, L | 1 |
| Li, J | 1 |
| Zuo, Y | 1 |
| Dang, D | 1 |
| Frost, JA | 1 |
| Yang, Q | 1 |
| Uhelski, ML | 1 |
| Khasabova, IA | 2 |
| Simone, DA | 2 |
| Kinsey, SG | 1 |
| Long, JZ | 1 |
| O'Neal, ST | 1 |
| Abdullah, RA | 1 |
| Poklis, JL | 1 |
| Boger, DL | 1 |
| Cravatt, BF | 1 |
| Lichtman, AH | 1 |
| Nodera, H | 1 |
| Spieker, A | 1 |
| Sung, M | 1 |
| Rutkove, S | 1 |
| Kaji, R | 1 |
| Khasabov, S | 1 |
| Paz, J | 1 |
| Harding-Rose, C | 1 |
| Seybold, VS | 1 |
| Aurora, RN | 1 |
| Kristo, DA | 1 |
| Bista, SR | 1 |
| Rowley, JA | 1 |
| Zak, RS | 1 |
| Casey, KR | 1 |
| Lamm, CI | 1 |
| Tracy, SL | 1 |
| Rosenberg, RS | 1 |
| Guindon, J | 1 |
| Lai, Y | 1 |
| Takacs, SM | 1 |
| Bradshaw, HB | 1 |
| Hohmann, AG | 1 |
| Field, MJ | 1 |
| Gonzalez, MI | 1 |
| Tallarida, RJ | 1 |
| Singh, L | 1 |
| Dost, R | 1 |
| Rostock, A | 1 |
| Rundfeldt, C | 1 |
| Liberatore, AM | 1 |
| Schulz, J | 1 |
| Favre-Guilmard, C | 1 |
| Pommier, J | 1 |
| Lannoy, J | 1 |
| Pawlowski, E | 1 |
| Barthelemy, MA | 1 |
| Huchet, M | 1 |
| Auguet, M | 1 |
| Chabrier, PE | 1 |
| Bigg, D | 1 |
| Maljevic, S | 1 |
| Wuttke, TV | 1 |
| Lerche, H | 1 |
| Fournier, E | 1 |
| Dally, S | 1 |
| Cambier, J | 1 |
| Umehara, F | 1 |
| Izumo, S | 1 |
| Arimura, K | 1 |
| Osame, M | 1 |
| Igata, A | 1 |
2 reviews available for carbamates and Peripheral Nerve Diseases
| Article | Year |
|---|---|
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evide | 2012 |
Nervous system KV7 disorders: breakdown of a subthreshold brake.
Topics: Anticonvulsants; Carbamates; Epilepsy, Benign Neonatal; Humans; KCNQ Potassium Channels; Mutation; N | 2008 |
14 other studies available for carbamates and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Target enzymes in oxaliplatin-induced peripheral neuropathy in Swiss mice: A new acetylcholinesterase inhibitor as therapeutic strategy.
Topics: Adenosine Triphosphatases; Analgesics; Animals; Anxiety; Benzoates; Carbamates; Cerebral Cortex; Cho | 2022 |
Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice.
Topics: Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Inflammation; Knee Joint; Male; Mice; | 2017 |
Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Drug Rep | 2019 |
Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonists; Carbamate | 2015 |
Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Topics: Amidohydrolases; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Benzamides; Benzodioxoles; Ca | 2009 |
Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy.
Topics: Action Potentials; Animals; Carbamates; Cisplatin; Disease Models, Animal; Drug Interactions; Inject | 2011 |
A potassium channel opener for neuropathy, motor neuron disease and beyond.
Topics: Animals; Carbamates; Cisplatin; Male; Neuroprotective Agents; Peripheral Nervous System Diseases; Ph | 2011 |
Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Ca | 2012 |
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c
Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Benzodio | 2013 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease | 2004 |
Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.
Topics: Animals; Batrachotoxins; Binding, Competitive; Carbamates; Carrageenan; Humans; Hyperalgesia; Imidaz | 2007 |
[Letter: Peripheral neuropathy probably due to anticholinesterasic insecticides].
Topics: Adult; Asthenia; Carbamates; Cholinesterase Inhibitors; Female; Humans; Insecticides; Male; Organoph | 1976 |
[Polyneuropathy in carbamate (m-tolyl methylcarbamate) poisoning].
Topics: Carbamates; Female; Humans; Insecticides; Middle Aged; Nerve Degeneration; Peripheral Nervous System | 1987 |